TOKYO, Mar 2, 2022 – (JCN Newswire via SEAPRWire.com) – Fujitsu today announced that it was the first company in the world to be honored by the Global Patient Advocacy Coalition of the International Headache Society(1)(IHS-GPAC) as a world leader in migraine workplace awareness, education, and employee support programs. Figure 1: Accreditation from IHS-GPAC to... » read more
TOKYO, Jul 1, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. Eisai... » read more
TOKYO, Mar 17, 2021 – (JCN Newswire via SEAPRWire.com) – Deutsches Zentrum fur Neurodegenerative Erkrankungen and Eisai Co., Ltd. today announced that both parties have entered into a research collaboration agreement aiming to create potential novel treatments for neurodegenerative disorders including Alzheimer’s disease (AD) which modulate immune competence in neurons and glia cells. DZNE is... » read more
TOKYO, Mar 2, 2021 – (JCN Newswire) – Eisai Co., Ltd. announced that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has obtained approval for the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. This approval... » read more